COMPASS Pathways(CMPS) - 2023 Q3 - Quarterly Report

Table of Contents • adding new clinical trial sites; • availability of adequately trained therapists and appropriate third-party clinical trial sites for the administration of COMP360 psilocybin treatment in our Phase 3 program and other clinical trials, including preparation, psilocybin administration and integration of the therapeutic experience; • sufficiency of any supporting digital services that may form part of the preparation, integration or long-term follow-up relating to any drug we develop; • fai ...